

Ugo De Giorgi

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1206625/publications.pdf>

Version: 2024-02-01

221
papers

12,773
citations

44069

48
h-index

28297

105
g-index

224
all docs

224
docs citations

224
times ranked

13127
citing authors

#	ARTICLE	IF	CITATIONS
1	Nivolumab in Combination with Stereotactic Body Radiotherapy in Pretreated Patients with Metastatic Renal Cell Carcinoma. Results of the Phase II NIVES Study. <i>European Urology</i> , 2022, 81, 274-282.	1.9	55
2	A European, prospective, observational study of enzalutamide in patients with metastatic castration-resistant prostate cancer: PREMISE. <i>International Journal of Cancer</i> , 2022, 150, 837-846.	5.1	14
3	Combining liquid biopsy and functional imaging analysis in metastatic castration-resistant prostate cancer helps predict treatment outcome. <i>Molecular Oncology</i> , 2022, 16, 538-548.	4.6	4
4	Plasma tumor <scp>DNA</scp> is associated with increased risk of venous thromboembolism in metastatic castration-resistant cancer patients. <i>International Journal of Cancer</i> , 2022, 150, 1166-1173.	5.1	4
5	Infigratinib in Early-Line and Salvage Therapy for FGFR3-Altered Metastatic Urothelial Carcinoma. <i>Clinical Genitourinary Cancer</i> , 2022, 20, 35-42.	1.9	5
6	Cabozantinib beyond progression improves survival in advanced renal cell carcinoma patients: the CABEYOND study (Meet-URO 21). <i>Expert Review of Anticancer Therapy</i> , 2022, 22, 115-121.	2.4	5
7	Immunotherapy and Sonpavde score validation in advanced upper tract urothelial carcinoma: a retrospective study by the Italian Network for Research in Urologic-Oncology (Meet-URO group). <i>Immunotherapy</i> , 2022, 14, 107-114.	2.0	4
8	Efficacy and safety of erdafitinib in patients with locally advanced or metastatic urothelial carcinoma: long-term follow-up of a phase 2 study. <i>Lancet Oncology</i> , The, 2022, 23, 248-258.	10.7	73
9	Circulating tumor cell gene expression and plasma AR gene copy number as biomarkers for castration-resistant prostate cancer patients treated with cabazitaxel. <i>BMC Medicine</i> , 2022, 20, 48.	5.5	8
10	Immune-Checkpoint Inhibitors in Advanced Bladder Cancer: Seize the Day. <i>Biomedicines</i> , 2022, 10, 411.	3.2	11
11	Application of the Meet-URO score to metastatic renal cell carcinoma patients treated with second- and third-line cabozantinib. <i>Therapeutic Advances in Medical Oncology</i> , 2022, 14, 175883592210795.	3.2	10
12	Cabozantinib in Patients with Advanced Renal Cell Carcinoma Primary Refractory to First-line Immunocombinations or Tyrosine Kinase Inhibitors. <i>European Urology Focus</i> , 2022, 8, 1696-1702.	3.1	17
13	Nivolumab VERSUS Cabozantinib as Second-Line Therapy in Patients With Advanced Renal Cell Carcinoma: A Real-World Comparison. <i>Clinical Genitourinary Cancer</i> , 2022, 20, 285-295.	1.9	5
14	Final Overall Survival and Molecular Analysis in IMmotion151, a Phase 3 Trial Comparing Atezolizumab Plus Bevacizumab vs Sunitinib in Patients With Previously Untreated Metastatic Renal Cell Carcinoma. <i>JAMA Oncology</i> , 2022, 8, 275.	7.1	75
15	Effect of systemic therapies or best supportive care after disease progression to both nivolumab and cabozantinib in metastatic renal cell carcinoma: The <scp>Meet-URO 19BEYOND</scp> study. <i>Cancer Medicine</i> , 2022, 11, 3084-3092.	2.8	4
16	Apalutamide, Darolutamide and Enzalutamide for Nonmetastatic Castration-Resistant Prostate Cancer (nmCRPC): A Critical Review. <i>Cancers</i> , 2022, 14, 1792.	3.7	15
17	Endometrioid Cancer Associated With Endometriosis: From the Seed and Soil Theory to Clinical Practice. <i>Frontiers in Oncology</i> , 2022, 12, 859510.	2.8	5
18	A fully virtual and nationwide molecular tumor board for gynecologic cancer patients: the virtual experience of the MITO cooperative group. <i>International Journal of Gynecological Cancer</i> , 2022, 32, 1205-1207.	2.5	5

#	ARTICLE	IF	CITATIONS
19	Role of Bone Metastases in Patients Receiving Immunotherapy for Pre-Treated Urothelial Carcinoma: The Multicentre, Retrospective Meet-URO-1 Bone Study. <i>Clinical Genitourinary Cancer</i> , 2022, 20, 155-164.	1.9	10
20	Concomitant Proton Pump Inhibitors and Outcome of Patients Treated with Nivolumab Alone or Plus Ipilimumab for Advanced Renal Cell Carcinoma. <i>Targeted Oncology</i> , 2022, 17, 61-68.	3.6	61
21	Decrease of Pro-Angiogenic Monocytes Predicts Clinical Response to Anti-Angiogenic Treatment in Patients with Metastatic Renal Cell Carcinoma. <i>Cells</i> , 2022, 11, 17.	4.1	7
22	Baseline Plasma Tumor DNA (ctDNA) Correlates with PSA Kinetics in Metastatic Castration-Resistant Prostate Cancer (mCRPC) Treated with Abiraterone or Enzalutamide. <i>Cancers</i> , 2022, 14, 2219.	3.7	5
23	Compassionate Use Program of Ipilimumab and Nivolumab in Intermediate or Poor Risk Metastatic Renal Cell Carcinoma: A Large Multicenter Italian Study. <i>Cancers</i> , 2022, 14, 2293.	3.7	4
24	High exosomal PD-L1 expression in relation to lymph node progression in metastatic castration-resistant prostate cancer (mCRPC) treated with abiraterone (abi) or enzalutamide (enza).. <i>Journal of Clinical Oncology</i> , 2022, 40, e17038-e17038.	1.6	0
25	Adherence to oral treatments in elderly patients with advanced prostate cancer: The ADHERE study, a prospective trial of the Meet-URO network.. <i>Journal of Clinical Oncology</i> , 2022, 40, 12044-12044.	1.6	2
26	Statin use improves the efficacy of nivolumab in patients with advanced renal cell carcinoma. <i>European Journal of Cancer</i> , 2022, 172, 191-198.	2.8	8
27	Atezolizumab plus Bevacizumab Versus Sunitinib for Patients with Untreated Metastatic Renal Cell Carcinoma and Sarcomatoid Features: A Prespecified Subgroup Analysis of the IMmotion151 Clinical Trial. <i>European Urology</i> , 2021, 79, 659-662.	1.9	64
28	The cyclin-dependent kinases pathway as a target for prostate cancer treatment: rationale and future perspectives. <i>Critical Reviews in Oncology/Hematology</i> , 2021, 157, 103199.	4.4	16
29	Clinical Outcomes of Patients With Metastatic Urothelial Carcinoma After Progression to Immune Checkpoint Inhibitors: A Retrospective Analysis by the Meet-Uro Group (Meet-URO 1 Study). <i>Clinical Medicine Insights: Oncology</i> , 2021, 15, 117955492110216.	1.3	12
30	New Prognostic Biomarkers in Metastatic Castration-Resistant Prostate Cancer. <i>Cells</i> , 2021, 10, 193.	4.1	26
31	Flare phenomenon in prostate cancer: recent evidence on new drugs and next generation imaging. <i>Therapeutic Advances in Medical Oncology</i> , 2021, 13, 175883592098765.	3.2	19
32	Immunotherapy and Its Development for Gynecological (Ovarian, Endometrial and Cervical) Tumors: From Immune Checkpoint Inhibitors to Chimeric Antigen Receptor (CAR)-T Cell Therapy. <i>Cancers</i> , 2021, 13, 840.	3.7	17
33	The prognostic significance of lactate dehydrogenase levels in seminoma patients with advanced disease: an analysis by the Global Germ Cell Tumor Collaborative Group (G3). <i>World Journal of Urology</i> , 2021, 39, 3407-3414.	2.2	4
34	Lenvatinib plus Pembrolizumab or Everolimus for Advanced Renal Cell Carcinoma. <i>New England Journal of Medicine</i> , 2021, 384, 1289-1300.	27.0	956
35	Treatment of Metastatic Urothelial Carcinoma After Previous Cisplatin-based Chemotherapy for Localized Disease: A Retrospective Comparison of Different Chemotherapy Regimens. <i>Clinical Genitourinary Cancer</i> , 2021, 19, 125-134.	1.9	4
36	INfluenza Vaccine Indication During therapy with Immune checkpoint inhibitors: a multicenter prospective observational study (INVIDIa-2). , 2021, 9, e002619.		17

#	ARTICLE	IF	CITATIONS
37	Vitamin D Deficiency in Testicular Cancer Survivors: A Systematic Review. International Journal of Molecular Sciences, 2021, 22, 5145.	4.1	2
38	Survival and New Prognosticators in Metastatic Seminoma: Results From the IGCCCG-Update Consortium. Journal of Clinical Oncology, 2021, 39, 1553-1562.	1.6	83
39	Predicting Outcomes in Men With Metastatic Nonseminomatous Germ Cell Tumors (NSGCT): Results From the IGCCCG Update Consortium. Journal of Clinical Oncology, 2021, 39, 1563-1574.	1.6	108
40	Prognostic Role of Circulating Tumor Cells in Metastatic Renal Cell Carcinoma: A Large, Multicenter, Prospective Trial. Oncologist, 2021, 26, 740-750.	3.7	19
41	An update on our ability to monitor castration-resistant prostate cancer dynamics with cell-free DNA. Expert Review of Molecular Diagnostics, 2021, 21, 631-640.	3.1	4
42	Post-traumatic stress symptoms in long-term disease-free cancer survivors and their family caregivers. Cancer Medicine, 2021, 10, 3974-3985.	2.8	16
43	Characteristics and outcome of BRCA mutated epithelial ovarian cancer patients in Italy: A retrospective multicenter study (MITO 21). Gynecologic Oncology, 2021, 161, 755-761.	1.4	9
44	Impact of Previous Nephrectomy on Clinical Outcome of Metastatic Renal Carcinoma Treated With Immune-Oncology: A Real-World Study on Behalf of Meet-URO Group (MeetUro-7b). Frontiers in Oncology, 2021, 11, 682449.	2.8	16
45	Sequencing Life-Prolonging Agents in Castration-Resistant Prostate Cancer Patients: Comparison of Sequences With and Without 223Ra. Cancer Biotherapy and Radiopharmaceuticals, 2021, 36, 391-396.	1.0	2
46	Circulating androgen receptor gene amplification and resistance to 177Lu-PSMA-617 in metastatic castration-resistant prostate cancer: results of a Phase 2 trial. British Journal of Cancer, 2021, 125, 1226-1232.	6.4	13
47	From Distress Screening to Uptake: An Italian Multicenter Study of Cancer Patients. Cancers, 2021, 13, 3761.	3.7	10
48	Moving beyond PARP Inhibition: Current State and Future Perspectives in Breast Cancer. International Journal of Molecular Sciences, 2021, 22, 7884.	4.1	8
49	Plasma androgen receptor and response to adapted and standard docetaxel regimen in castration-resistant prostate cancer: A multicenter biomarker study. European Journal of Cancer, 2021, 152, 49-59.	2.8	4
50	Melphalan as a Promising Treatment for BRCA-Related Ovarian Carcinoma. Frontiers in Oncology, 2021, 11, 716467.	2.8	8
51	Targeted radioactive therapy for prostate cancer. Lancet, The, 2021, 398, 487-488.	13.7	0
52	A phase 3 randomised study of enzalutamide plus leuprolide and enzalutamide monotherapy in high-risk non-metastatic hormone-sensitive prostate cancer with rising PSA after local therapy: EMBARK study design. BMJ Open, 2021, 11, e046588.	1.9	14
53	Cabozantinib in Pretreated Patients with Metastatic Renal Cell Carcinoma with Sarcomatoid Differentiation: A Real-World Study. Targeted Oncology, 2021, 16, 625-632.	3.6	6
54	Talazoparib: a new biomarker-directed therapy in advanced prostate cancer. Lancet Oncology, The, 2021, 22, 1203-1204.	10.7	1

#	ARTICLE	IF	CITATIONS
55	Inflammatory indices and clinical factors in metastatic renal cell carcinoma patients treated with nivolumab: the development of a novel prognostic score (Meet-URO 15 study). <i>Therapeutic Advances in Medical Oncology</i> , 2021, 13, 175883592110196.	3.2	36
56	Body Mass Index in Patients Treated with Cabozantinib for Advanced Renal Cell Carcinoma: A New Prognostic Factor?. <i>Diagnostics</i> , 2021, 11, 138.	2.6	13
57	Clinical Outcomes of Metastatic Renal Carcinoma Following Disease Progression to Programmed Death (PD)-1 or PD-L1 Inhibitors (IO). <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 2021, 44, 121-125.	1.3	12
58	Primary Mediastinal and Testicular Germ Cell Tumors in Adolescents and Adults: A Comparison of Genomic Alterations and Clinical Implications. <i>Cancers</i> , 2021, 13, 5223.	3.7	10
59	Radiotherapy and High-Dose Interleukin-2: Clinical and Immunological Results of a Proof of Principle Study in Metastatic Melanoma and Renal Cell Carcinoma. <i>Frontiers in Immunology</i> , 2021, 12, 778459.	4.8	6
60	Prognostic and Predictive Factors in Advanced Urothelial Carcinoma Treated with Immune Checkpoint Inhibitors: A Review of the Current Evidence. <i>Cancers</i> , 2021, 13, 5517.	3.7	8
61	An Italian, multicenter, real-world, retrospective study of first-line pazopanib in unselected metastatic renal-cell carcinoma patients: the "Pamerit" study. <i>Japanese Journal of Clinical Oncology</i> , 2021, 51, 484-491.	1.3	1
62	First-line pazopanib in patients with advanced non-clear cell renal carcinoma: An Italian case series. <i>World Journal of Clinical Oncology</i> , 2021, 12, 1037-1046.	2.3	2
63	Consistent survival benefit of enzalutamide plus androgen deprivation therapy in men with nonmetastatic castration-resistant prostate cancer: PROSPER subgroup analysis by age and region. <i>European Journal of Cancer</i> , 2021, 159, 237-246.	2.8	6
64	Treatment Outcome of metastatic lesions from renal cell carcinoma under Going Extra-cranial stereotactic body radiotherapy: The together retrospective study. <i>Cancer Treatment and Research Communications</i> , 2020, 22, 100161.	1.7	18
65	Survival Outcomes From a Cumulative Analysis of Worldwide Observational Studies on Sequential Use of New Agents in Metastatic Castration-Resistant Prostate Cancer. <i>Clinical Genitourinary Cancer</i> , 2020, 18, 69-76.e4.	1.9	11
66	An 1H NMR study of the cytarabine degradation in clinical conditions to avoid drug waste, decrease therapy costs and improve patient compliance in acute leukemia. <i>Anti-Cancer Drugs</i> , 2020, 31, 67-72.	1.4	1
67	Real-World Data on Cabozantinib in Previously Treated Patients with Metastatic Renal Cell Carcinoma: Focus on Sequences and Prognostic Factors. <i>Cancers</i> , 2020, 12, 84.	3.7	22
68	Plasma AR Copy Number Changes and Outcome to Abiraterone and Enzalutamide. <i>Frontiers in Oncology</i> , 2020, 10, 567809.	2.8	5
69	Potential Application of Chimeric Antigen Receptor (CAR)-T Cell Therapy in Renal Cell Tumors. <i>Frontiers in Oncology</i> , 2020, 10, 565857.	2.8	14
70	Hyperphosphatemia Secondary to the Selective Fibroblast Growth Factor Receptor 3 Inhibitor Infigratinib (BGJ398) Is Associated with Antitumor Efficacy in Fibroblast Growth Factor Receptor 3-altered Advanced/Metastatic Urothelial Carcinoma. <i>European Urology</i> , 2020, 78, 916-924.	1.9	18
71	Plasma tumour DNA as an early indicator of treatment response in metastatic castration-resistant prostate cancer. <i>British Journal of Cancer</i> , 2020, 123, 982-987.	6.4	22
72	Symptomatic COVID-19 in advanced-cancer patients treated with immune-checkpoint inhibitors: prospective analysis from a multicentre observational trial by FICOG. <i>Therapeutic Advances in Medical Oncology</i> , 2020, 12, 175883592096846.	3.2	14

#	ARTICLE	IF	CITATIONS
73	68Ga-PSMA-11 PET/CT-Guided Stereotactic Body Radiation Therapy Retreatment in Prostate Cancer Patients with PSA Failure after Salvage Radiotherapy. <i>Biomedicines</i> , 2020, 8, 536.	3.2	11
74	Enzalutamide for the treatment of nonmetastatic castration-resistant prostate cancer. Expert Opinion on Pharmacotherapy, 2020, 21, 2091-2099.	1.8	8
75	Prognostic Role of Systemic Inflammatory Indexes in Germ Cell Tumors Treated With High-Dose Chemotherapy. <i>Frontiers in Oncology</i> , 2020, 10, 1325.	2.8	14
76	Inflammatory indexes as predictive factors for platinum sensitivity and as prognostic factors in recurrent epithelial ovarian cancer patients: a MITO24 retrospective study. <i>Scientific Reports</i> , 2020, 10, 18190.	3.3	16
77	Durvalumab alone and durvalumab plus tremelimumab versus chemotherapy in previously untreated patients with unresectable, locally advanced or metastatic urothelial carcinoma (DANUBE): a randomised, open-label, multicentre, phase 3 trial. <i>Lancet Oncology</i> , The, 2020, 21, 1574-1588.	10.7	324
78	Ki67 and PR in Patients Treated with CDK4/6 Inhibitors: A Real-World Experience. <i>Diagnostics</i> , 2020, 10, 573.	2.6	13
79	Dosimetry and safety of 177Lu PSMA-617 along with polyglutamate parotid gland protector: preliminary results in metastatic castration-resistant prostate cancer patients. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2020, 47, 3008-3017.	6.4	37
80	Atezolizumab with or without chemotherapy in metastatic urothelial cancer (IMvigor130): a multicentre, randomised, placebo-controlled phase 3 trial. <i>Lancet</i> , The, 2020, 395, 1547-1557.	13.7	546
81	Human chorionic gonadotropin- α -positive seminoma patients: A registry compiled by the global germ cell tumor collaborative group (G3). <i>European Journal of Cancer</i> , 2020, 132, 127-135.	2.8	8
82	Enzalutamide and Survival in Nonmetastatic, Castration-Resistant Prostate Cancer. <i>New England Journal of Medicine</i> , 2020, 382, 2197-2206.	27.0	253
83	Impact of influenza syndrome and flu vaccine on survival of cancer patients during immunotherapy in the INVIDia study. <i>Immunotherapy</i> , 2020, 12, 151-159.	2.0	16
84	Infigratinib in upper tract urothelial carcinoma versus urothelial carcinoma of the bladder and its association with comprehensive genomic profiling and/or cell-free DNA results. <i>Cancer</i> , 2020, 126, 2597-2606.	4.1	39
85	Immune Modulation in Prostate Cancer Patients Treated with Androgen Receptor (AR)-Targeted Therapy. <i>Journal of Clinical Medicine</i> , 2020, 9, 1950.	2.4	3
86	A comprehensive review of the role of immune checkpoint inhibitors in elderly patients affected by renal cell carcinoma. <i>Critical Reviews in Oncology/Hematology</i> , 2020, 153, 103036.	4.4	5
87	Adherence to abiraterone or enzalutamide in elderly metastatic castration-resistant prostate cancer. <i>Supportive Care in Cancer</i> , 2020, 28, 4687-4695.	2.2	16
88	Combined Oral Fentanyl Citrate and Midazolam as Premedication for Bone Marrow Aspiration and Biopsy in Patients with Hematological Malignancies: A Randomized, Controlled and Patient-Blinded Clinical Trial. <i>Journal of Clinical Medicine</i> , 2020, 9, 395.	2.4	4
89	Neutrophil-to-lymphocyte ratio and lactate dehydrogenase as biomarkers for urothelial cancer treated with immunotherapy. <i>Clinical and Translational Oncology</i> , 2020, 22, 2130-2135.	2.4	31
90	Effect of Enzalutamide plus Androgen Deprivation Therapy on Health-related Quality of Life in Patients with Metastatic Hormone-sensitive Prostate Cancer: An Analysis of the ARCHES Randomised, Placebo-controlled, Phase 3 Study. <i>European Urology</i> , 2020, 78, 603-614.	1.9	30

#	ARTICLE	IF	CITATIONS
91	Effect of Baseline Characteristics on Cabazitaxel Treatment Duration in Patients with Metastatic Castration-Resistant Prostate Cancer: A Post Hoc Analysis of the Compassionate Use/Expanded Access Programs and CAPRISTANA Registry. <i>Cancers</i> , 2020, 12, 995.	3.7	2
92	Immunosenescence in Testicular Cancer Survivors: Potential Implications of Cancer Therapies and Psychological Distress. <i>Frontiers in Oncology</i> , 2020, 10, 564346.	2.8	7
93	Genome-wide plasma DNA methylation features of metastatic prostate cancer. <i>Journal of Clinical Investigation</i> , 2020, 130, 1991-2000.	8.2	68
94	Olaparib as salvage treatment for advanced germ cell tumors after chemotherapy failure: Results of the open-label, single-arm, IGG-02 phase II trial.. <i>Journal of Clinical Oncology</i> , 2020, 38, 5058-5058.	1.6	9
95	Final overall survival (OS) from PROSPER: A phase III, randomized, double-blind, placebo (PBO)-controlled study of enzalutamide (ENZA) in men with nonmetastatic castration-resistant prostate cancer (nmCRPC).. <i>Journal of Clinical Oncology</i> , 2020, 38, 5515-5515.	1.6	17
96	Treatment of metastatic recurrence of urothelial carcinoma after previous cisplatin-based chemotherapy: A retrospective comparison of different chemotherapy regimens.. <i>Journal of Clinical Oncology</i> , 2020, 38, e17005-e17005.	1.6	0
97	Baseline and early change of neutrophil to lymphocyte ratio (bNLR and \hat{I}^*NLR) as prognostic factors in metastatic renal cell carcinoma (mRCC) treated with Nivolumab: Final results of the Meet-URO 15 (I-BIO-REC) study.. <i>Journal of Clinical Oncology</i> , 2020, 38, e17081-e17081.	1.6	0
98	Randomized Phase II Study Evaluating Akt Blockade with Ipatasertib, in Combination with Abiraterone, in Patients with Metastatic Prostate Cancer with and without PTEN Loss. <i>Clinical Cancer Research</i> , 2019, 25, 928-936.	7.0	232
99	Safety and efficacy of nivolumab for metastatic renal cell carcinoma: realâ€world results from an expanded access programme. <i>BJU International</i> , 2019, 123, 98-105.	2.5	70
100	Association between circulating tumor cells and peripheral blood monocytes in metastatic breast cancer. <i>Therapeutic Advances in Medical Oncology</i> , 2019, 11, 175883591986606.	3.2	35
101	Role and relevance of quality indicators in the selection of first-line treatment of patients with metastatic renal cell carcinoma: a position paper of the MeetURO Group. <i>Future Oncology</i> , 2019, 15, 2657-2666.	2.4	1
102	Testosterone levels and androgen receptor copy number variations in castrationâ€resistant prostate cancer treated with abiraterone or enzalutamide. <i>Prostate</i> , 2019, 79, 1211-1220.	2.3	17
103	Therapeutic Challenges for Cisplatin-Resistant Ovarian Germ Cell Tumors. <i>Cancers</i> , 2019, 11, 1584.	3.7	16
104	CAR-T cell therapy: a potential new strategy against prostate cancer. , 2019, 7, 258.		61
105	Inflammatory Biomarkers as Predictors of Response to Immunotherapy in Urological Tumors. <i>Journal of Oncology</i> , 2019, 2019, 1-11.	1.3	6
106	Plasma Androgen Receptor in Prostate Cancer. <i>Cancers</i> , 2019, 11, 1719.	3.7	13
107	Second line therapy with axitinib after only prior sunitinib in metastatic renal cell cancer: Italian multicenter real world SAX study final results. <i>Journal of Translational Medicine</i> , 2019, 17, 296.	4.4	13
108	Severe Complications in Testicular Germ Cell Tumors: The Choriocarcinoma Syndrome. <i>Frontiers in Endocrinology</i> , 2019, 10, 218.	3.5	30

#	ARTICLE	IF	CITATIONS
109	Immune System and DNA Repair Defects in Ovarian Cancer: Implications for Locoregional Approaches. International Journal of Molecular Sciences, 2019, 20, 2569.	4.1	18
110	Caregiver Emotional Burden in Testicular Cancer Patients: From Patient to Caregiver Support. Frontiers in Endocrinology, 2019, 10, 318.	3.5	9
111	Plasma AR status and cabazitaxel in heavily treated metastatic castration-resistant prostate cancer. European Journal of Cancer, 2019, 116, 158-168.	2.8	29
112	Atezolizumab plus bevacizumab versus sunitinib in patients with previously untreated metastatic renal cell carcinoma (IMmotion151): a multicentre, open-label, phase 3, randomised controlled trial. Lancet, The, 2019, 393, 2404-2415.	13.7	778
113	State of the art about influenza vaccination for advanced cancer patients receiving immune checkpoint inhibitors: When common sense is not enough. Critical Reviews in Oncology/Hematology, 2019, 139, 87-90.	4.4	21
114	Early use of abiraterone and radium-223 in metastatic prostate cancer. Lancet Oncology, The, 2019, 20, e228.	10.7	7
115	Multimodal Approach to Outcome Prediction in Metastatic Castration-Resistant Prostate Cancer by Integrating Functional Imaging and Plasma DNA Analysis. JCO Precision Oncology, 2019, 3, 1-13.	3.0	8
116	Reclassification of good-risk seminoma: prognostic factors, novel biomarkers and implications for clinical management. Future Oncology, 2019, 15, 1347-1352.	2.4	4
117	Activity and safety of metronomic cyclophosphamide in the modern era of metastatic castration-resistant prostate cancer. Future Oncology, 2019, 15, 1115-1123.	2.4	9
118	Association of Systemic Inflammation Index and Body Mass Index with Survival in Patients with Renal Cell Cancer Treated with Nivolumab. Clinical Cancer Research, 2019, 25, 3839-3846.	7.0	147
119	Real-world efficacy and safety of nivolumab in previously-treated metastatic renal cell carcinoma, and association between immune-related adverse events and survival: the Italian expanded access program. , 2019, 7, 99.		110
120	The MITO CERV-2 trial: A randomized phase II study of cetuximab plus carboplatin and paclitaxel, in advanced or recurrent cervical cancer. Gynecologic Oncology, 2019, 153, 535-540.	1.4	19
121	The effect of a treatment delay on outcome in metastatic renal cell carcinoma. Urologic Oncology: Seminars and Original Investigations, 2019, 37, 529.e1-529.e7.	1.6	5
122	Psychosocial Issues in Long-Term Survivors of Testicular Cancer. Frontiers in Endocrinology, 2019, 10, 113.	3.5	39
123	The Interplay between Inflammation, Anti-Angiogenic Agents, and Immune Checkpoint Inhibitors: Perspectives for Renal Cell Cancer Treatment. Cancers, 2019, 11, 1935.	3.7	21
124	Safety and Efficacy of Cabozantinib for Metastatic Nonclear Renal Cell Carcinoma. American Journal of Clinical Oncology: Cancer Clinical Trials, 2019, 42, 42-45.	1.3	20
125	Targeted therapies for advanced bladder cancer: new strategies with FGFR inhibitors. Therapeutic Advances in Medical Oncology, 2019, 11, 175883591989028.	3.2	74
126	Safety and Efficacy of Pazopanib in First-Line Metastatic Renal-Cell Carcinoma With or Without Renal Failure: CORE-URO-01 Study. Clinical Genitourinary Cancer, 2019, 17, e150-e155.	1.9	9

#	ARTICLE	IF	CITATIONS
127	Plasma Androgen Receptor and Docetaxel for Metastatic Castration-resistant Prostate Cancer. <i>European Urology</i> , 2019, 75, 368-373.	1.9	64
128	Circulating androgen receptor (AR) gene amplification and resistance to 177Lu-PSMA-617 in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC): Results of a phase II clinical trial.. <i>Journal of Clinical Oncology</i> , 2019, 37, 3020-3020.	1.6	3
129	Infigratinib in upper tract urothelial carcinoma vs urothelial carcinoma of the bladder and association with comprehensive genomic profiling/cell-free DNA results.. <i>Journal of Clinical Oncology</i> , 2019, 37, 4510-4510.	1.6	7
130	Phase II study of avelumab in multiple relapsed/refractory testicular germ cell cancer.. <i>Journal of Clinical Oncology</i> , 2019, 37, e16045-e16045.	1.6	2
131	Systemic immune-inflammation index in germ-cell tumours. <i>British Journal of Cancer</i> , 2018, 118, 831-838.	6.4	70
132	Association among metabolic syndrome, inflammation, and survival in prostate cancer. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2018, 36, 240.e1-240.e11.	1.6	20
133	Atezolizumab versus chemotherapy in patients with platinum-treated locally advanced or metastatic urothelial carcinoma (IMvigor211): a multicentre, open-label, phase 3 randomised controlled trial. <i>Lancet</i> , The, 2018, 391, 748-757.	13.7	1,142
134	Lenvatinib in the management of metastatic renal cell carcinoma: a promising combination therapy?. <i>Expert Opinion on Drug Metabolism and Toxicology</i> , 2018, 14, 461-467.	3.3	9
135	PSMA expression: a potential ally for the pathologist in prostate cancer diagnosis. <i>Scientific Reports</i> , 2018, 8, 4254.	3.3	128
136	Radical cystectomy or bladder preservation with radiochemotherapy in elderly patients with muscle-invasive bladder cancer: Retrospective International Study of Cancers of the Urothelial Tract (RISC) Investigators. <i>Acta Oncol</i> , 2018, 57, 491-497.	1.8	22
137	Prognostic value of 18Fâ€“choline PET/CT metabolic parameters in patients with metastatic castration-resistant prostate cancer treated with abiraterone or enzalutamide. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2018, 45, 348-354.	6.4	22
138	Re: Marzia Del Re, Elisa Biasco, Stefania Crucitta, et al. The Detection of Androgen Receptor Splice Variant 7 in Plasma-derived Exosomal RNA Strongly Predicts Resistance to Hormonal Therapy in Metastatic Prostate Cancer Patients. <i>Eur Urol</i> 2017;71:680â€“7. <i>European Urology</i> , 2018, 73, e9-e10.	1.9	1
139	Oxaliplatin plus leucovorin and 5-fluorouracil (FOLFOX-4) as a salvage chemotherapy in heavily-pretreated platinum-resistant ovarian cancer. <i>BMC Cancer</i> , 2018, 18, 1267.	2.6	12
140	Plasma androgen receptor and serum chromogranin A in advanced prostate cancer. <i>Scientific Reports</i> , 2018, 8, 15442.	3.3	21
141	Enzalutamide after chemotherapy in advanced castration-resistant prostate cancer: the Italian Named Patient Program. <i>Future Oncology</i> , 2018, 14, 2691-2699.	2.4	3
142	Is It Possible to Improve Prognostic Classification in Patients Affected by Metastatic Renal Cell Carcinoma With an Intermediate or Poorâ€“Prognosis?. <i>Clinical Genitourinary Cancer</i> , 2018, 16, 355-359.e1.	1.9	31
143	Efficacy of BGJ398, a Fibroblast Growth Factor Receptor 1â€“3 Inhibitor, in Patients with Previously Treated Advanced Urothelial Carcinoma with <i>FGFR3</i> Alterations. <i>Cancer Discovery</i> , 2018, 8, 812-821.	9.4	206
144	TARIBO trial: targeted therapy with or without nephrectomy in metastatic renal cell carcinoma: liquid biopsy for biomarkers discovery. <i>Tumori</i> , 2018, 104, 401-405.	1.1	10

#	ARTICLE	IF	CITATIONS
145	Immune-Related Concepts in Biology and Treatment of Germ-Cell Tumors. <i>Advances in Urology</i> , 2018, 2018, 1-6.	1.3	6
146	68Ga-PSMA PET/CT in patients with recurrent prostate cancer after radical treatment: prospective results in 314 patients. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2018, 45, 2035-2044.	6.4	72
147	Inflammatory Indexes as Prognostic and Predictive Factors in Ovarian Cancer Treated with Chemotherapy Alone or Together with Bevacizumab. A Multicenter, Retrospective Analysis by the MITO Group (MITO 24). <i>Targeted Oncology</i> , 2018, 13, 469-479.	3.6	38
148	[177 Lu]-PSMA-617 for targeted prostate cancer treatment: a magic bullet?. <i>Lancet Oncology</i> , The, 2018, 19, 725-726.	10.7	9
149	Reply to the letter to the editor "Androgen deprivation therapy and risk of rheumatoid arthritis in patients with localized prostate cancer" by Yang et al.. <i>Annals of Oncology</i> , 2018, 29, 1879-1880.	1.2	1
150	Safety and Efficacy of Cabozantinib in Metastatic Renal-Cell Carcinoma: Real-World Data From an Italian Managed Access Program. <i>Clinical Genitourinary Cancer</i> , 2018, 16, e945-e951.	1.9	30
151	68Ga-PSMA-PET: added value and future applications in comparison to the current use of choline-PET and mpMRI in the workup of prostate cancer. <i>Radiologia Medica</i> , 2018, 123, 952-965.	7.7	16
152	Sequencing of Taxanes and New Androgen-targeted Therapies in Metastatic Castration-resistant Prostate Cancer: Results of the International Multicentre Retrospective CATS Database. <i>European Urology Oncology</i> , 2018, 1, 467-475.	5.4	25
153	AR Copy Number and AR Signaling-directed Therapies in Castration-resistant Prostate Cancer. <i>Current Cancer Drug Targets</i> , 2018, 18, 869-876.	1.6	3
154	Molecular Mechanisms of Resistance in Testicular Germ Cell Tumors - clinical Implications. <i>Current Cancer Drug Targets</i> , 2018, 18, 967-978.	1.6	14
155	Long-term clinical impact of PSA surge in castration-resistant prostate cancer patients treated with abiraterone. <i>Prostate</i> , 2017, 77, 1012-1019.	2.3	6
156	A Phase II Study of Everolimus Plus Oral Prednisone in Patients with Metastatic Renal Cell Cancer. <i>Oncologist</i> , 2017, 22, 784-e74.	3.7	1
157	Clinical outcome of patients who reduced sunitinib or pazopanib during first-line treatment for advanced kidney cancer. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2017, 35, 541.e7-541.e13.	1.6	10
158	High-Dose Chemotherapy for Adult-Type Ovarian Granulosa Cell Tumors: A Retrospective Study of the European Society for Blood and Marrow Transplantation. <i>International Journal of Gynecological Cancer</i> , 2017, 27, 248-251.	2.5	3
159	Reduction of 68Ga-PSMA renal uptake with mannitol infusion: preliminary results. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2017, 44, 2189-2194.	6.4	30
160	Urinary RNA-based biomarkers for prostate cancer detection. <i>Clinica Chimica Acta</i> , 2017, 473, 96-105.	1.1	39
161	International evaluation of the psychometrics of health-related quality of life questionnaires for use among long-term survivors of testicular and prostate cancer. <i>Health and Quality of Life Outcomes</i> , 2017, 15, 97.	2.4	18
162	Immunotherapy for Prostate Cancer: Where We Are Headed. <i>International Journal of Molecular Sciences</i> , 2017, 18, 2627.	4.1	47

#	ARTICLE	IF	CITATIONS
163	Circulating tumor cells (CTCs) are associated with abnormalities in peripheral blood dendritic cells in patients with inflammatory breast cancer. <i>Oncotarget</i> , 2017, 8, 35656-35668.	1.8	44
164	Vitamin D status among long-term survivors of testicular cancer. <i>Oncotarget</i> , 2017, 8, 36780-36786.	1.8	14
165	Outcome of oligoprogressing metastatic renal cell carcinoma patients treated with locoregional therapy: a multicenter retrospective analysis. <i>Oncotarget</i> , 2017, 8, 100708-100716.	1.8	32
166	<i>GSTP1</i> Methylation and Protein Expression in Prostate Cancer: Diagnostic Implications. <i>Disease Markers</i> , 2016, 2016, 1-6.	1.3	68
167	Systemic immune-inflammation index predicts the clinical outcome in patients with metastatic renal cell cancer treated with sunitinib. <i>Oncotarget</i> , 2016, 7, 54564-54571.	1.8	116
168	CYP17A1 Polymorphisms and Clinical Outcome of Castration-Resistant Prostate Cancer Patients Treated with Abiraterone. <i>International Journal of Biological Markers</i> , 2016, 31, 264-269.	1.8	10
169	Clinical Impact of Pancreatic Metastases from Renal Cell Carcinoma: A Multicenter Retrospective Analysis. <i>PLoS ONE</i> , 2016, 11, e0151662.	2.5	56
170	Persistent Neutrophil to Lymphocyte Ratio ≥ 3 during Treatment with Enzalutamide and Clinical Outcome in Patients with Castration-Resistant Prostate Cancer. <i>PLoS ONE</i> , 2016, 11, e0158952.	2.5	45
171	Axitinib after Sunitinib in Metastatic Renal Cancer: Preliminary Results from Italian "Real-World" SAX Study. <i>Frontiers in Pharmacology</i> , 2016, 7, 331.	3.5	13
172	Systemic Immune-Inflammation Index Predicts the Clinical Outcome in Patients with mCRPC Treated with Abiraterone. <i>Frontiers in Pharmacology</i> , 2016, 7, 376.	3.5	127
173	Cell-free DNA as a diagnostic marker for cancer: current insights. <i>OncoTargets and Therapy</i> , 2016, Volume 9, 6549-6559.	2.0	104
174	Methylation pattern analysis in prostate cancer tissue: identification of biomarkers using an MS-MLPA approach. <i>Journal of Translational Medicine</i> , 2016, 14, 249.	4.4	16
175	Urothelial Cancer: Inflammatory Mediators and Implications for Immunotherapy. <i>BioDrugs</i> , 2016, 30, 263-273.	4.6	22
176	Association Between Early PSA Increase and Clinical Outcome in Patients Treated with Enzalutamide for Metastatic Castration Resistant Prostate Cancer. <i>Molecular Diagnosis and Therapy</i> , 2016, 20, 255-263.	3.8	10
177	Pharmacokinetics, pharmacodynamics and clinical efficacy of nivolumab in the treatment of metastatic renal cell carcinoma. <i>Expert Opinion on Drug Metabolism and Toxicology</i> , 2016, 12, 1089-1096.	3.3	17
178	Phase III Study of Cabozantinib in Previously Treated Metastatic Castration-Resistant Prostate Cancer: COMET-1. <i>Journal of Clinical Oncology</i> , 2016, 34, 3005-3013.	1.6	202
179	Re: Pasquale Rescigno, David Lorente, Diletta Bianchini, et al. Prostate-specific Antigen Decline After 4 Weeks of Treatment with Abiraterone Acetate and Overall Survival in Patients with Metastatic Castration-resistant Prostate Cancer. <i>Eur Urol</i> 2016;70:724-31. <i>European Urology</i> , 2016, 70, e168-e169.	1.9	1
180	The potential use of urine cell free DNA as a marker for cancer. <i>Expert Review of Molecular Diagnostics</i> , 2016, 16, 1283-1290.	3.1	39

#	ARTICLE	IF	CITATIONS
181	Correlation of Stomatitis and Cutaneous Toxicity With Clinical Outcome in Patients With Metastatic Renal-Cell Carcinoma Treated With Everolimus. <i>Clinical Genitourinary Cancer</i> , 2016, 14, 426-431.	1.9	9
182	Clinical outcomes in octogenarians treated with docetaxel as first-line chemotherapy for castration-resistant prostate cancer. <i>Future Oncology</i> , 2016, 12, 493-502.	2.4	8
183	Adjuvant Carboplatin Treatment in 115 Patients With Stage I Seminoma: Retrospective Multicenter Survey. <i>Clinical Genitourinary Cancer</i> , 2016, 14, e161-e169.	1.9	16
184	Safety and Clinical Outcomes of Abiraterone Acetate After Docetaxel in Octogenarians With Metastatic Castration-Resistant Prostate Cancer: Results of the Italian Compassionate Use Named Patient Programme. <i>Clinical Genitourinary Cancer</i> , 2016, 14, 48-55.	1.9	14
185	Role of DNA repair machinery and p53 in the testicular germ cell cancer: a review. <i>Oncotarget</i> , 2016, 7, 85641-85649.	1.8	22
186	Inflammatory indexes as predictors of prognosis and bevacizumab efficacy in patients with metastatic colorectal cancer. <i>Oncotarget</i> , 2016, 7, 33210-33219.	1.8	128
187	Circulating <i>AR</i> copy number and outcome to enzalutamide in docetaxel-treated metastatic castration-resistant prostate cancer. <i>Oncotarget</i> , 2016, 7, 37839-37845.	1.8	69
188	Metabolic syndrome in castration-resistant prostate cancer patients treated with abiraterone. <i>Prostate</i> , 2015, 75, 1329-1338.	2.3	24
189	Germ Cell Tumors Overexpress the Candidate Therapeutic target Cyclin B1 Independently of p53 function. <i>International Journal of Biological Markers</i> , 2015, 30, 275-281.	1.8	3
190	Urine Cell-Free DNA Integrity Analysis for Early Detection of Prostate Cancer Patients. <i>Disease Markers</i> , 2015, 2015, 1-6.	1.3	40
191	A Phase II Study of a Dose-Density Regimen With Fluorouracil, Epirubicin, and Cyclophosphamide on Days 1 and 4 Every 14 Days With Filgrastim Support Followed by Weekly Paclitaxel in Women With Primary Breast Cancer. <i>Oncologist</i> , 2015, 20, 239-240.	3.7	7
192	PSA Flare With Abiraterone in Patients With Metastatic Castration-Resistant Prostate Cancer. <i>Clinical Genitourinary Cancer</i> , 2015, 13, 39-43.	1.9	62
193	Clinical Outcomes of Castration-resistant Prostate Cancer Treatments Administered as Third or Fourth Line Following Failure of Docetaxel and Other Second-line Treatment: Results of an Italian Multicentre Study. <i>European Urology</i> , 2015, 68, 147-153.	1.9	73
194	Circulating tumor cells in newly diagnosed inflammatory breast cancer. <i>Breast Cancer Research</i> , 2015, 17, 2.	5.0	36
195	Clinical outcomes in a contemporary series of "young" patients with castration-resistant prostate cancer who were 60 years and younger. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2015, 33, 265.e15-265.e21.	1.6	6
196	18F-Fluorocholine PET/CT for early response assessment in patients with metastatic castration-resistant prostate cancer treated with enzalutamide. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2015, 42, 1276-1283.	6.4	83
197	Prognostic significance of host immune status in patients with late relapsing renal cell carcinoma treated with targeted therapy. <i>Targeted Oncology</i> , 2015, 10, 517-522.	3.6	49
198	High Neutrophil-to-lymphocyte Ratio Persistent During First-line Chemotherapy Predicts Poor Clinical Outcome in Patients with Advanced Urothelial Cancer. <i>Annals of Surgical Oncology</i> , 2015, 22, 1377-1384.	1.5	80

#	ARTICLE	IF	CITATIONS
199	Plasma <i>AR</i> and abiraterone-resistant prostate cancer. <i>Science Translational Medicine</i> , 2015, 7, 312re10.	12.4	366
200	Taxane-related nail toxicity. <i>Lancet Oncology</i> , The, 2015, 16, e310-e311.	10.7	8
201	Circulating tumor cells as early predictors of metastatic spread in breast cancer patients with limited metastatic dissemination. <i>Breast Cancer Research</i> , 2014, 16, 440.	5.0	94
202	Chromogranin A is a potential prognostic marker in prostate cancer patients treated with enzalutamide. <i>Prostate</i> , 2014, 74, 1691-1696.	2.3	52
203	Chromogranin A predicts outcome in prostate cancer patients treated with abiraterone. <i>Endocrine-Related Cancer</i> , 2014, 21, 487-493.	3.1	59
204	Recruiting long-term survivors of European Organisation for Research and Treatment of Cancer phase III clinical trials into quality of life studies: Challenges and opportunities. <i>European Journal of Cancer</i> , 2014, 50, 1957-1963.	2.8	4
205	Adjuvant High-Dose Chemotherapy with Autologous Hematopoietic Stem Cell Support for High-Risk Primary Breast Cancer: Results from the Italian National Registry. <i>Biology of Blood and Marrow Transplantation</i> , 2014, 20, 501-506.	2.0	7
206	Lymphopenia and clinical outcome of elderly patients treated with sunitinib for metastatic renal cell cancer. <i>Journal of Geriatric Oncology</i> , 2014, 5, 156-163.	1.0	22
207	Randomized, Controlled, Double-Blind, Cross-Over Trial Assessing Treatment Preference for Pazopanib Versus Sunitinib in Patients With Metastatic Renal Cell Carcinoma: PISCES Study. <i>Journal of Clinical Oncology</i> , 2014, 32, 1412-1418.	1.6	381
208	Neuroendocrine differentiation in prostate cancer: Current and emerging therapy strategies. <i>Critical Reviews in Oncology/Hematology</i> , 2014, 92, 11-24.	4.4	71
209	The emerging role of anti-angiogenic therapy in ovarian cancer. <i>International Journal of Oncology</i> , 2014, 44, 1417-1424.	3.3	18
210	Early outcome prediction on 18F-fluorocholine PET/CT in metastatic castration-resistant prostate cancer patients treated with abiraterone. <i>Oncotarget</i> , 2014, 5, 12448-12458.	1.8	92
211	Pazopanib versus Sunitinib in Metastatic Renal-Cell Carcinoma. <i>New England Journal of Medicine</i> , 2013, 369, 722-731.	27.0	1,648
212	Salvage treatment of relapsed or refractory germ-cell tumours. <i>Lancet Oncology</i> , The, 2013, 14, e486.	10.7	0
213	Value of pharmacokinetic studies for patients with gastrointestinal stromal tumors. <i>Future Oncology</i> , 2013, 9, 1675-1677.	2.4	0
214	Relationship Between Lymphocytopenia and Circulating Tumor Cells as Prognostic Factors for Overall Survival in Metastatic Breast Cancer. <i>Clinical Breast Cancer</i> , 2012, 12, 264-269.	2.4	87
215	Long-term outcome of salvage high-dose chemotherapy in patients with germ cell tumor with poor prognostic features. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2011, 29, 284-290.	1.6	10
216	Conventional-Dose Versus High-Dose Chemotherapy As First Salvage Treatment in Male Patients With Metastatic Germ Cell Tumors: Evidence From a Large International Database. <i>Journal of Clinical Oncology</i> , 2011, 29, 2178-2184.	1.6	226

#	ARTICLE	IF	CITATIONS
217	¹⁸ F-FDG PET/CT Findings and Circulating Tumor Cell Counts in the Monitoring of Systemic Therapies for Bone Metastases from Breast Cancer. Journal of Nuclear Medicine, 2010, 51, 1213-1218.	5.0	60
218	Prognostic Factors in Patients With Metastatic Germ Cell Tumors Who Experienced Treatment Failure With Cisplatin-Based First-Line Chemotherapy. Journal of Clinical Oncology, 2010, 28, 4906-4911.	1.6	267
219	Phase II Study of Oxaliplatin and Gemcitabine Salvage Chemotherapy in Patients with Cisplatin-Refractory Nonseminomatous Germ Cell Tumor. European Urology, 2006, 50, 1032-1039.	1.9	64
220	Salvage high-dose chemotherapy in patients with germ cell tumors. Cancer, 2002, 95, 309-315.	4.1	27
221	Inflammatory Biomarkers for Outcome Prediction in Patients With Metastatic Testicular Cancer. Frontiers in Oncology, 0, 12, .	2.8	3